Aditxt Signs Collaboration Agreement with Salveo Diagnostics to Commercialize AditxtScore™ Platform Starting in Q4, 2020
September 03 2020 - 9:00AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies focused on improving the health of the immune
system through immune monitoring and reprogramming, today announced
that it has signed a Collaboration Agreement with Salveo
Diagnostics, Inc., a CLIA and CAP Accredited laboratory
company focused on end-to-end personalized medicine solutions aimed
at preventing, stopping, and reversing the epidemic of chronic
disease.
Aditxt believes that the collaboration provides it
with access to a regulatory path, operational foundation and sales
channels that will enable the Company to accelerate the launch of
theAditxtScore™ platform. Aditxt will be seeking to utilize
Salveo’s facilities and capabilities as a launching pad for
commercializing AditxtScore™ starting in Q4, 2020. As previously
announced, Aditxt submitted an Emergency Use Authorization
(EUA) application with the U.S. Food and Drug Administration (FDA)
for AditxtScore™ for COVID-19, for use in detecting antibodies
against SARS-CoV-2 antigens.
Amro Albanna, Co-founder and Chief Executive
Officer of Aditxt, stated, “The collaboration with Salveo is the
first step towards commercializing AditxtScore. With the
completion of the recently announced $9.6 million follow-on
offering and this partnership, we believe that we are now
positioned to advance AditxtScore as a key growth driver for
Aditxt.”
Mark Chapman, CEO of Salveo, added, “We believe
that the AditxtScore platform will add to the abilities of the
diagnostic industry as Aditxt continues to introduce applications,
such as predicting immune responses to vaccination and early
detection of Type I Diabetes, among others. We look forward to
partnering with the team at Aditxt to pursuing and expanding
commercial and consumer opportunities in the health and wellness
space, ultimately resulting in better health for consumers of all
ages.”
About Salveo Diagnostics
Headquartered in Richmond, VA, Salveo Diagnostics,
Inc. is a state-of-the-art laboratory that offers biomarker testing
designed to detect underlying patient health trends and conditions
early, creating an opportunity for prevention and reversal of
disease. Through their advanced propriety algorithm, Salveo
Diagnostics provides a unique platform to help clinicians uncover
the root cause of their patients' symptoms, offering a real
alternative to the "one-size-fits-all" approach. Using high-quality
testing with evidence-based biomarkers of gastrointestinal health,
cardiometabolic health, nutritional health, hormonal health and
many others, we help guide individualized therapies to provide
focused support for patients on their journey to being well.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit www.aditxt.com.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward-looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated June 29, 2020, that was filed with the U.S.
Securities and Exchange Commission under File No. 333-235933, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the U.S.
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:PCG
AdvisoryJeff RamsonChief Executive
Officer646-762-4518IR@aditxt.com www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024